Friday, May 26, 2017

Orphan Drugs As Hot Properties...

...If you know how to squeeze the system, and the right participants, at the right places. There's profit potential for you, and boy aren't they just making the most of it.

When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs

With a flagship treatment that helps fewer than 11,000 people, how is Alexion making so much money?